Effects of the angiotensin II receptor antagonist losartan on herpes simplex virus-type 2 infection of cultured vero and cardiac neonatal myocytes.
Previous studies indicate that captopril, an angiotensin II converting enzyme inhibitor, attenuates cardiomyopathy in a murine viral myocarditis model. Accordingly, we investigated the ability of captopril as well as angiotensin II (AII) and losartan, a nonpeptide AII receptor antagonist, to alter infection or replication of herpes simplex virus- type 2 (HSV-2) in cultured cardiac and vero cells. Neither captopril nor AII influenced the ability of HSV-2 to replicate in either cell type. Losartan, however, caused a dose dependent decrease in pfu ability on vero cells with an ED50 of 1.35 mM. In cultured myocytes, losartan (400 microM) reduced significantly %LDH released (54.9 +/- 7.5 vs 29.1 +/- 4.2 in infected controls) and % pfu released (40.9 +/- 8.4 vs 14.8 +/- 3.8 in infected controls) into the media. These results suggest that losartan attenuates deleterious effects of the virus by preventing release of the virus by the cells.
Department of Biology, West Chester University, PA 19383.
P L
PL
Gardner
G N
GN
Mbuy
M T
MT
Knabb
D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D002216:Captopril / Q000494:pharmacology; D002478:Cells, Cultured; D006321:Heart / Q000187:drug effects* / Q000196:embryology / Q000382:microbiology; D018258:Herpesvirus 2, Human / Q000187:drug effects* / Q000502:physiology; D007093:Imidazoles / Q000494:pharmacology*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D019808:Losartan; D009206:Myocardium / Q000201:enzymology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013777:Tetrazoles / Q000494:pharmacology*; D014709:Vero Cells / Q000382:microbiology*; D010948:Viral Plaque Assay
D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D007093:Imidazoles; D013777:Tetrazoles; D002216:Captopril; D007770:L-Lactate Dehydrogenase; D019808:Losartan